As Rousseff Impeachment Looms Could Her Successor Help Pharma In Brazil?
Executive Summary
Brazil is not an easy place to do business at the moment. Its economy is in deep recession, its political class is mired in a far-reaching corruption scandal and now it looks increasingly likely that President Dilma Rousseff will be impeached for fiddling the figures to make the fiscal deficit look better. "But from the very bottom, the only place to go is up," says Benny Spiewak, from the Brazilian law firm Zancaner Costa, Bastos and Spiewak. He thinks a new leader could do much for pharmaceutical R&D and restore relations with an embattled industry.
You may also be interested in...
Brazil, Mexico Taking Divergent Paths On Regulatory Reform
Anvisa is in the process of trying to reduce some of its red tape, but the excessive bureaucracy at COFEPRIS is likely to remain in place for the foreseeable future.
Brazilian Notebook: Key Themes From BIO Latin America
Population size and favorable biosimilar policies highlight the opportunities for biotech in Brazil, but economic turmoil and other factors pose challenges.
Brazilian Notebook: Key Themes From BIO Latin America
Population size and favorable biosimilar policies highlight the opportunities for biotech in Brazil, but economic turmoil and other factors pose challenges.